Professional Documents
Culture Documents
Received: 13 November 2000 Abstract Anti-epileptic drugs are degradation of GABA. Other pro-
Accepted in revised form: 5 April 2001 employed for the prophylactic treat- posed mechanisms of action for val-
ment of migraine. Valproic acid and proate are a direct effect on neuronal
its sodium salt (divalproex) have membranes and a reduction of exci-
been shown to be effective in pre- tatory transmission by aspartate.
venting migraine in double-blind Valproate, at the recommended dose
placebo-controlled studies. of 500 mg twice daily, is well toler-
Gabapentin and lamotrigine have ated. The more frequent unwanted
also been proposed for migraine pro- effects associated with almost all
phylaxis, but more extensive studies drugs of this class are weight gain,
are needed to confirm their effica- drowsiness, dizziness and tremor.
cies. The main mechanism of action Topiramate has recently been pro-
of anti-epileptic drugs is the inhibi- posed for the treatment of unrespon-
tion of the sodium channel to induce sive, high frequency migraine, taking
L.-A. Pini () • L. Lupo a depolarization, preventing the high, into account both the GABA and glu-
Internal Medicine Department,
University of Modena and Reggio Emilia,
frequent action potentials typically tamatergic mechanisms of action.
Via Del Pozzo 71, I-41100 Modena, Italy excited by convulsive attacks.
e-mail: pinila@unimo.it Moreover, valproate and gabapentin Key words Antiepileptic drugs •
Tel.: +39-059-4224065 increase brain concentrations of Prophylactic treatment • Migraine •
Fax: +39-059-4224069 GABA and, probably, inhibit the Headache
venting migraine attacks, may take 3–6 months. In con- ilar to that of both phenytoin and carbamazepine, and
trolled clinical trials, efficacy is often first noted after four appears to be mediated by a prolonged recovery of voltage-
weeks and continues to increase for three months. It is not activated Na+ channels from inactivation [3].
uncommon for patients to be treated with a new preventive Another probable mechanism that may contribute to val-
medication for 1–2 weeks without effect and for the treat- proate’s antiseizure action involves metabolism of gamma-
ment to be prematurely discontinued with both patient and aminobutyric acid (GABA). The increase of brain GABA
physician believing it was not effective [2]. concentrations depends on inhibition of both GABA amino-
To obtain maximal benefit from preventive medication, transferase and succinic dehydrogenase, enzymes involved
the patient should not overuse analgesics or ergot deriva- in the synthesis and degradation of GABA. Selective
tives. In addition, oral contraceptives, hormonal replace- increases of GABA have been reported to occur in synapto-
ment therapy or vasodilating drugs such as nifedipine or somes, primarily in areas of high GABA activity after val-
nitroglycerin may interfere with preventive drugs [2]. proate administration. On the other hand, valproate inhibits
Recently, sodium valproate and other anticonvulsive GABA re-uptake and reduces glutamate by activating glu-
drugs have been more widely employed in preventive treat- tamic acid decarboxylase.
ment of migraine with good results. These drugs reduce the The enhancement of GABA activity in the brain, from
firing response of neurons by acting on membrane ion chan- increased GABA synthesis and decreased GABA degrada-
nels or by acting on the GABA system. We do not know the tion, has been assumed to be the mechanism of action in pre-
mode of action of these drug in preventing migraine. venting migraine attacks [4]. Moreover, divalproex sodium
Therefore, clinical evidence precedes the pharmacological acts on the brain serotonin system by enhancing the GABA-
explanation. This implies that the evaluation of prophylactic mediated inhibition of serotonin neurons of the dorsal raphe
treatments for migraine needs to be carried out with care, area and raising the threshold of the onset of migraine [5].
and that results should be analyzed taking into account the Finally, this drug prevents vasodilatation during
lack of pharmacological basis for this therapy (Table 1). migraine attacks [4].
In this review, we discuss the use of anti-epileptic drugs Oral absorption is rapid, and occurs within 1–4 h. Peak
in the preventive treatment of migraine attacks. serum concentrations range from 50 to 100 µg/ml and the
volume of distribution is 0.130–0.23 l/kg. Protein binding is
91% and cerebrospinal fluid levels reach 10% of plasma
concentrations. Elimination half-life ranges from 8 to 17
Sodium valproate hours, and extensive hepatic metabolism is followed by
renal excretion. Approximately 1.8%–3.2% of the adminis-
Sodium valproate is a classic anti-epileptic drug used since tered dose is excreted without modification, while 7% is
1978. Its chemical structure is a simple branched-chain car- excreted in the bile within 7 h of administration.
boxylic acid. At therapeutic concentrations, valproate Well-recognized adverse effects are thrombocytopenia,
inhibits sustained repetitive firing induced by depolarization hemorrhage, red cell aplasia, tremor, ataxia, fatigue, seda-
of mouse cortical or spinal cord neurons. The action is sim- tion, abdominal cramps, dizziness, sedation, confusion,
15
IHS, International Headache Society classification; 1.1, migraine without aura; 1.2, migraine with aura
headache, nausea, diarrhea, alopecia and weight gain. In a In a recently study, sodium valproate was used intra-
long-term study of sodium valproate therapy (48–60 venously for the acute treatment of migraine attacks. A
months), almost all patients gained weight whereas only group of 32 female patients with a history of refractory
14% experienced tremors [6, 7]. severe headache received 500 mg sodium valproate.
Concurrent use of primidone and valproic acid may Valproate was well tolerated with minimal side effects. After
result in severe central nervous system depression. Aspirin, one hour, complete relief was recorded in 8 patients, and at
erythromycin or felbamate may increase valproic acid toxi- 24 hours 12 patients referred complete pain relief. Only one
city (CNS depression). Fosphenytoin, acyclovir, imipenem, patient referred transient somnolence [10].
isoniazid, phenobarbital and rifampicin may result in altered In another study the efficacy and tolerability of repetitive
valproate levels. intravenous sodium valproate and intravenous dihydroergo-
For migraine headache prophylaxis, 500–1000 mg/kg tamine (DHE) in intractable migraine were examined [11].
day in divided doses was used by Klapper in a dose- Intravenous sodium valproate was as effective as intra-
response study that showed no improvement in activity up venous DHE in breaking intractable migraine attacks, but it
doses of 1000 mg/day (Table 2) [8]. was associated with less adverse events. In conclusion, these
studies suggest that valproate may be used along with other
migraine abortives.
Clinical studies
IHS, International Headache Society; 1.1, migraine without aura; 1.2, migraine with aura
17
migraine and chronic daily headache with dosages ranging attempting to become pregnant may still require preventive
from 50 to 800 mg/day. Treatment of headache with topira- medication. In these cases, the preventive treatment should
mate was associated with loss of weight [25]. take into account the potential teratogenic risk compared to
In conclusion, these results suggest that topiramate is the therapeutic benefit.
effective in the prophylactic treatment of migraine. An underweight patient is a candidate for medication
that increases appetite, such as cyproheptadine, flunarizine
or tricyclic antidepressants (TCA) [25, 26]. In contrast, a
young woman with dietary problems should avoid these
Conclusions drugs. Moreover, the type of employment should be evalu-
ated, because TCA, flunarizine and pizotifen can impair
The goals of preventive treatment are to optimize the qual- attention and create dangerous situations for those who
ity of life for patients. The medications used to prevent drive or use machines.
migraine fall into two major categories. First-line drugs Comorbidity and coexisting diseases can provide thera-
have high efficacy and include β-blockers, tricyclic antide- peutic opportunities in the choice of a drug, but in the same
pressants, calcium-channel blockers such as flunarizine, way they impose therapeutic limitations. In the case of coex-
and divalproex sodium. This category also includes drugs isting hypertension or angina, β-blockers and verapamil
with lower demonstrated efficacy such as selective sero- may be considered effective for the treatment of both dis-
tonin reuptake inhibitors (SSRIs), verapamil, nimodipine eases. Patients with depression should be treated successful-
and NSAIDs. Second-line, high efficacy drugs include ly with TCA or SSRIs, and migraneurs suffering from
pizotifen, monoamino-oxidase inhibitors and drugs with seizures can be treated with divalproex sodium or other anti-
unproved or low efficacy, including cyproheptadine, lithi- epileptic drugs.
um and phenytoin. This category also includes new anti- On the other hand, patients may have diseases that con-
epileptic drugs. traindicate some drugs. For example, β-blockers such as flu-
The choice of a preventive drug must involve the accu- narizine should be used carefully in patients with depres-
rate evaluation of the clinical characteristics of the patients, sion. TCA and neuroleptics, used in acute treatment in emer-
with attention to their age, sex, life style and co-morbidity. gency wards, can lower seizure threshold and should be
In fact, only a complete evaluation of these parameters can used with caution in epileptic migraneurs [2, 26].
allow a correct evaluation of the best risk-to-benefit ratio for Preventive medications are considered to be effective
the individual patient and take advantage of the side-effect when the reduction of the number of headaches is over 50%
profile of the drug (Table 4). [2]. The anti-epileptic drugs that we have reported in this
A woman of childbearing potential should be on ade- paper have been studied to detect this goal, and results are
quate contraception before starting migraine medication. often encouraging, even if not conclusive. Some of these
However, some women who are pregnant or who are drugs, such as valproate and flunarizine, are certainly of
MAO-I, monoamino-oxidase I; CHF, chronic heart failure; OCD, obsessive compulsive disorders
19
first-choice in the prevention of migraine attacks, whereas The main goal we have is the improvement of the quali-
other drugs such as lamotrigine, gabapentin and topiramate ty of life of our patients, and these newer drugs or these new
are useful in resistant headaches or in neuropathic pain syn- indications can enlarge our possibility to find the best drug
dromes. for the single patient.
References
1. Silberstein SD, Lipton RB (1994) 11. Mathew NT, Kailasam J (2000) 19. Freitag GF, Diamond S, Diamond ML
Overview of diagnosis and treatment Repetitive intravenous administration (1999) Tiagabine in the prophylaxis of
of migraine. Neurology 44:6 of valproate sodium in intractable migraine. Neurology 52[Suppl 2]:A208
2. Silberstei SD, Lipton BR, Goadsby PJ migraine: comparison with intravenous 20. Edwards KR, Glantz MJ, Norton A,
(1998) Headache in clinical practice. dihydroergotamine. Neurology Cross N (2000) Prophylactic treatment
ISIS Medical Media, Oxford, pp 59–90 54[Suppl 3]:A22 of episodic migraine with topiramate: a
3. McLean MJ, Macdonald RL (1986) 12. Nicolodi M, Sicuteri F (1998) double-blind, placebo-controlled trial
Sodium valproate, but not ethosux- Negative modulors of excitatory amino in 30 patients. Cephalalgia 20:316
imide, produces use and voltage- acid in episodic and chronic migraine: 21. Wheeler SD, Carrazzana EJ (2000)
dependent limitation of high frequency preventing and reverting chronic Topiramate-responsive cluster
repetitive firing of action potentials of migraine. Int J Clin Pharmacol Res headache. Cephalalgia 20:325–331
mouse central neurons in cell culture. J 18(2):93–100 22. Potter DL, Hart DE, Calder CS, Storey
Pharmacol Exp 237:1001–1011 13. Di Trapani G, Mei D, Marra C, Mazza JR (2000) A double-blind, randomized,
4. Silberstein SD (1996) Divalproex sodi- S, Capuano A (2000) Gabapentin in the placebo controlled, parallel study to
um in headache: literature review and prophylaxis of migraine: a double- determine the efficacy of Topamax
clinical guidelines. Headache blind, randomized, placebo-controlled (Topiramate) in the prophylactic of
36(9):547–555 study. Cephalalgia 20:338–357 migraine. Neurology 54[Suppl 3]:A14
5. Mathew NT, Saper JR, Silberstein SD 14. D’Andrea G, Granella F, Cadaldini M, 23. Di Trapani G, Mei D, Marra C, Mazza
et al (1995) Migraine prophylaxis with Manzoni GC (1999) Effectiveness of S, Capuano A (2000) Use of
divalproex. Arch Neurol 52:281–286 lamotrigine in the prophylaxis of Topiramate as prophylactic treatment
6. Ghose K (1999) Long term efficacy migraine with aura: an open pilot study in migraine: result of a pilot study.
and safety of sodium valproate in Cephalalgia 19:64–66 Cephalalgia 20:338–357
patients with drug resistant migraine. 15. Lampl C, Buzath A, Klinger D, 24. Randal L, Von Seggern, Mannix Lisa
Headache Quaterly 10(2):127–113 Neuman K (1999) Lamotrigine in the K, James U (2000) Efficacy of
7. Dreifuss FE, Langer DH (1998) Side prophylactic treatment of migraine Topiramate in migraine prophylaxis: a
effects of valproate. Am J Med aura: a pilot a study. Cephalalgia retrospective chart analysis. Neurology
84[Suppl 1A]:34–41 19(1):58–63 54[Suppl 3]:A267
8. Klapper J (1997) Divalproex sodium in 16. Steiner TJ, Findley LJ, Yuen AW 25. Young WB, Hopkins MM, Sanchez
migraine prophylaxis: a dose-con- (1997) Lamotrigine versus placebo in Del Rio M, Shechter AL (2000) The
trolled study. Cephalalgia the prophylaxis of migraine with and effect of Topiramate on weight in
17(2):103–108 without aura. Cephalalgia 109–112 chronic daily headache and episodic
9. Ghose K, Niven B (1998) Prophylactic 17. D’Andrea G, Bussone G, Granella F, migraine patients. Cephalalgia
sodium valproate therapy in patients Leone M, Rigamonti A, Nappi G 20:338–357
with drug-resistant migraine. Methods (2000) Treatment of SUNCT syndrome 26. Silberstein SD (1997) Preventive
Find Exp Clin Pharmacol 20:353–359 with lamotrigine. Cephalalgia headache treatment. Cephalalgia
10. Robins L (2000) Intravenous valproate 20:377–384 17:67–72
for prolonged migraine headache. 18. D’Andrea G, Granella F, Cadaldini M
Cephalalgia 20:333 (1999) Possible usefulness of lamotrig-
ine in the treatment of SUNCT syn-
drome. Neurology 22:53(7):1609